Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
September 03, 2024 03:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
May 23, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
January 24, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
January 24, 2024 03:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
September 26, 2023 09:30 ET | Source: Amphista Therapeutics

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or...